恶性肿瘤患者化疗相关贫血的治疗  

Treatment of chemotherapy-related anemia in malignant tumor patients

作　　者：潘海霞[1] 邓春美[1] 任刚[1] 朱学强[1] 邓颖[1] 杨兰 敖睿[1] 胡洪林[1] 刘浩[1] 

机构地区：[1]四川省人民医院肿瘤科,四川成都610072

出　　处：《四川医学》2011年第10期1522-1524,共3页Sichuan Medical Journal

摘　　要：目的本课题研究我科恶性肿瘤患者化疗后贫血的发生状况及药物干预治疗。方法选择我科2008年1月～2010年7月收治的化疗前血红蛋白正常的肿瘤患者82例,统计化疗后贫血的发生率,贫血的程度,含铂与非含铂方案对贫血的影响,对发生贫血的患者分为两组,单药组单用促红细胞生成素10000U,皮下注射,每周3次,连续8周治疗36例;联合组给予促红细胞生成素10000U,皮下注射,每周3次,和蔗糖铁0.2g,静脉滴注,每周2次,连续8周治疗37例,观察治疗前后血红蛋白的变化及不良反应。结果 82例恶性肿瘤患者化疗后贫血的发生率为85.37%,其中轻度贫血37例(45.12%),中度贫血22例(26.83%),重度贫血9例(10.98%),极重度贫血2例(2.44%),无贫血12例(14.63%)。单药组治疗后血红蛋白平均升高(20.1±3.3)g/L,联合组治疗后血红蛋白平均升高(22.1±3.5)g/L,两组比较差异有统计学意义。化疗后贫血发生以轻到中度为主(71.95%),含铂方案贫血发生率90.63%,非含铂方案贫血发生率66.67%,两组比较差异有统计学意义。未见促红细胞生成素和蔗糖铁的明显不良作用。结论恶性肿瘤患者化疗后贫血的发生率高,含铂方案的化疗导致贫血的发生率更高。促红细胞生成素、蔗糖铁能纠正恶性肿瘤患者化疗所致的贫血,两者联合使用疗效更佳。Objective This topic studies the anemia and drug intervention therapy after malignant tumor＇ chemotherapies in our division.Methods Recruit eighty two tumor＇ survivors whose hemoglobin are normal before chemotherapy from January 2008 to July 2010,and count the anemia＇s incidence rate and extent after chemotherapies.Discuss the effects in standard platinum-based regimen and no platinum-based regimen and divide these anemia＇ patients into two groups.Use 10000IU erythropoietin and hypodermically injection three times a week in monotherapy group,and cure 36 patients in continuous 8 weeks.Use 10000IU erythropoietin for hypodermically injection three times a week and 0.2 Iron sucrose for intravenous infusions two times a week in combined administration group,and cure 37 patients in continuous 8 weeks.Observe hemoglobin and side effect before and after treatment.Results The anemia＇s incidence rate is 85.37%.The middle anemia is 45.12%（37 persons）,and the medium anemia is 26.83%（22 persons）,and the high anemia is 10.98%（9 persons）,and the life-threatening anemia is 2.44%（2 persons）,and the no anemia is 14.63%（12 persons）.The average anemia elevation is（20.1±3.3）g/L and（22.1±3.5）g/L in monotherapy group and combined administration group respectively.The average anemia elevation is significantly different between the two groups.After chemotherapies,the total incidence rate is 71.95% about middle and medium anemia,and the anemia＇s incidence rate is 90.63% about standard platinum-based regimen,and is 66.67% about no platinum-based regimen,and there is significance in the two groups.There is no significant side effect after using erythropoietin and Iron sucrose.Conclusion the incidence rate of anemia is high after malignant tumor＇ chemotherapies,and is higher after standard platinum-based regimen.Erythropoietin and Iron sucrose can improve anemia what was induced by malignant tumor＇ chemotherapies.The effect is well after combined administration.

关 键 词：恶性肿瘤 化疗 贫血 促红细胞生成素 蔗糖铁 

分 类 号：R730.53[医药卫生—肿瘤] R556[医药卫生—临床医学]